WALTHAM, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that Manos Perros, President and Chief Executive Officer, will present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York, NY.

Event: BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Date: December 12, 2018 at 1:40 PM ET
Location: Mandarin Oriental Hotel, New York, NY

A live webcast of the presentation can be accessed under "Investors & Media" in the “News & Events” section of the Company's website at www.entasistx.com.

About Entasis
Entasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), ETX0282CPDP (targeting Enterobacteriaceae infections), and non-β-lactam PBP inhibitors or NBPs (targeting Gram-negative infections). www.entasistx.com

Company Contact                                                    
Kyle Dow 
Entasis Therapeutics   
(781) 810-0114       
kyle.dow@entasistx.com   

Investor Contact
Chris Brinzey
Westwicke Partners
(339) 970-2843
Chris.brinzey@westwicke.com

Media Contact
Kari Watson or Stefanie Tuck
MacDougall Biomedical Communications
(781) 235-3060
kwatson@macbiocom.com or stuck@macbiocom.com

Source: Entasis Therapeutics Holdings Inc.